AN2 Therapeutics (ANTX) Receivables - Other (2022 - 2026)
AN2 Therapeutics (ANTX) posted quarterly Receivables - Other of $300000.0 for Q1 2026, little changed year-over-year from $300000.0 in Q1 2025, and down 25.0% quarter-over-quarter from $400000.0 in Q4 2025.
Powered by 
Analysis
AN2 Therapeutics (ANTX) Receivables - Other (2022 - 2026) Analysis & Trends
AN2 Therapeutics (ANTX) has reported Receivables - Other for 5 consecutive years, with $300000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Receivables - Other changed 0.0% year-over-year to $300000.0; the TTM figure through Mar 2026 stood at $300000.0 (changed 0.0% YoY), while the FY2025 annual figure was $400000.0, up 33.33% from the prior year.
- Receivables - Other declined to $300000.0 in Q1 2026 per ANTX's latest filing, from $400000.0 in the prior quarter.
- Across five years, Receivables - Other topped out at $500000.0 in Q3 2023 and bottomed at $200000.0 in Q4 2022.
- Historically, Receivables - Other has averaged $328571.4 across 5 years, with a median of $300000.0 in 2024.
- Annual changes were most pronounced in 2023 — Receivables - Other jumped 100.0% — and 2024, when it tumbled 40.0%.
- AN2 Therapeutics' Receivables - Other stood at $200000.0 in 2022, then surged by 100.0% to $400000.0 in 2023, then retreated by 25.0% to $300000.0 in 2024, then jumped by 33.33% to $400000.0 in 2025, then retreated by 25.0% to $300000.0 in 2026.
- Business Quant data shows ANTX's Receivables - Other at $300000.0 in Q1 2026, $400000.0 in Q4 2025, and $400000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | AN2 Therapeutics | 262.30 Mn | 262.30 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 300,000.00 |
| Mar 31, 2026 | 300,000.00 |
| Dec 31, 2025 | 400,000.00 |
| Sep 30, 2025 | 400,000.00 |
| Jun 30, 2025 | 400,000.00 |
| Mar 31, 2025 | 300,000.00 |
| Dec 31, 2024 | 300,000.00 |
| Sep 30, 2024 | 300,000.00 |
| Jun 30, 2024 | 300,000.00 |
| Mar 31, 2024 | 400,000.00 |
| Dec 31, 2023 | 400,000.00 |
| Sep 30, 2023 | 500,000.00 |
| Jun 30, 2023 | 200,000.00 |
| Mar 31, 2023 | 200,000.00 |
| Dec 31, 2022 | 200,000.00 |